跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
aldometanib
首页
药物
aldometanib
aldometanib
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Application of compound Aldometanib in preparation of medicine for treating psoriasis
申请人: UNIV HENAN
优先权: 2026
CN
Application of AMPK activator Aldometanib in preparation of drugs for inhibiting inflammatory pain
申请人: UNIV HENAN
优先权: 2026
CN
Application of Aldometanib (Bigu, LXY-05-029) in medicine for treating tamoxifen drug-resistant breast cancer
申请人: NANJING JIEYIN DIAGNOSIS TECH CO LTD
优先权: 2023
CN
Application of Aldometanib in preparation of medicine for preventing and treating immune-related adverse reactions and diseases
申请人: FUJIAN CANCER HOSPITAL FUJIAN CANCER INST FUJIAN CANCER PREVENTION CENTER
优先权: 2025
CN
含GLS1抑制剂和AMPK激活剂的药物组合物及其用途
申请人: 厦门大学
优先权: 2024
CN
药物
反馈